Neurocrine Biosciences' Phase 2 SAVITRI study shows positive results for NBI-1065845 in treating major depressive disorder.
Neurocrine Biosciences' Phase 2 SAVITRI study shows positive results for NBI-1065845 in treating major depressive disorder. The AMPA positive allosteric modulator demonstrated statistically significant improvement in MADRS total score at both day 28 and day 56, meeting primary and key secondary endpoints. The treatment is generally well-tolerated and Neurocrine plans to discuss Phase 3 studies with the FDA.
April 23, 2024
4 Articles